Science

Overview

The primary focus of Moleculomics technologies are to provide molecular information to assist the discovery and development of new chemical compounds and therapeutics.  These technologies are the result of an academic track record of structural bioinformatics algorithm and software development since 2001. The resulting technologies are uniquely powerful and uniquely validated in their design, proofing and optimisation by extensive application to a number of protein families, including ion channels, transport proteins, enzymes, structural proteins, drug and viral receptors, reported in 40+ top quartile journal publications.

Structural Modelling and Molecular Docking
Moleculomics offers a bespoke protein structure prediction service for individual or small sets of proteins including variants.
Read more »
Toxicity Screening
High throughput affinity screening and docking of compounds against panels of proteins of known toxicity to identify and eliminate problem compounds earlier within the R&D cycle
Read more »
Tissue Specific Screening
High throughput affinity screening and docking of specified compounds against any of 47 tissue specific panels of proteins to provide molecular and structural information to evaluate compound efficacy and toxicity
Read more »
Whole Proteome Screening
High throughput affinity screening and docking of compounds against whole proteomes to provide comprehensive molecular and structural information to evaluate compound efficacy and toxicity
Read more »
Pathway Analysis
Annotated Protein-Protein Interaction data pertaining to link Molecular Initiation Events (MIEs) with an understanding of Modes of Action and tissue specific pathway analysis
Read more »
Technology Platforms
Prepopulated platforms of protein-ligand or protein-protein interactions developed to your specification providing high value molecular and structural information, integrated to your existing workflow
Read more »
Re-Drug: Drug Repositioning
Re-Drug is a comprehensive Artificial Intelligence-based screening technology for the assessment of both on-target (efficacy) and off-target (potential toxicity) of a candidate therapeutic drawn from the pool of around 1400 FDA approved drugs, screened for repositioning opportunities across more than 1400 known drug targets. This whole system framework provides an assessment of the candidate drug’s predicted behaviour based upon comparison with the established mechanistic data for a broad range of currently used drugs, encompassing both drug efficacy and potential toxicity.
Read more »
CRISP: Cross-species comparative in silico platform
Comparing liver protein interactions across human, mouse and rat. This tool helps researchers compare compound interactions with liver proteins across 3 species. A compound can be chosen, and a report is produced showing protein interactions in humans, associated pathways, and which proteins are most similar in mouse and rat. This is intended to help inform decisions about whether rat or mouse, or neither, is the most appropriate animal model for studying a specific interaction in humans.
Read more »

The structural modelling pipelines are based on both homology modelling and threading techniques to provide the most comprehensive and accurate outputs possible.   The structural modelling tools are supplemented with a series of tools to identify and derive a host of information relating to molecular interactions between structural models and compounds of interest.  These world leading tools include;

  • A protein modelling platform capable of modelling both wild-type and conformational differences of variant forms at pan-genome and multi-genome scale, based on both homology modelling and threading techniques to provide the most comprehensive and accurate outputs possible;
  • A machine learning based screening pipeline capable of systematically predicting and linking the interactions between proteins and molecules, to provide immensely valuable new knowledge of whole organism affinity and toxicity of millions of compounds and;
  • A structural-based high throughput platform integrated with an in vitro knowledgebase for the prediction of protein-protein interactions at whole genome scale.

The full scope of these technologies has been demonstrated in the establishment of whole proteome structural sets for human, two yeasts and a number of bacteria.  A series of tools have been developed, validated and applied to; protein modelling, lead discovery , toxicity screening  and pathway analysis tools .  For more information, please see the case studies below.

The Moleculomics technologies utilize the latest High Performance Computing approaches, scaled to identify interactions, not only at the targets of interest, but also elsewhere across the entire proteome or across several proteomes.

Increased scale of understanding of molecular interaction enables research and development times to be reduced by more rapid and wider identification of target hits while simultaneously reducing the risk of adverse or off-target interactions.

Moleculomics is the only company offering open-ended lead discovery, toxicity screening and protein network identification, that is completely unlimited in reach, and that is applied across multiple genomes.

Company Team
Find out more about the international team behind Moleculomics
Read more
Our Services
An overview of the current range of services which we have to offer
Read more
News
Latest company and industry news from the biosimulation sector
Read more
Contact Us
Contact a company representative to discuss your next project
Read more

START TYPING AND PRESS ENTER TO SEARCH